2 Percent Salicylic Acid Serum for Sebum Control and Pore Size Reduction

A Clinical Study Evaluate the Safety and Efficacy of 2 percent Salicylic Acid Serum for Sebum Control and Pore Size Reduction - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/06/111865

Enrollment

Registered

2026-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: 2% Salicylic Acid Serum: Test Product: 2% Salicylic Acid Serum Dose: :Apply 2-3 drops twice a day gently Route of Administration: Topical Control Intervention1: Not Applic

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Male & female aged between 18 to 45 2. Subject willing to give written informed consent 3. Subject having normal to oily skin with acne marks. 4. Subject with open pores. 5. Women of child bearing potential must have a negative urine pregnancy test 6.Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. 7.Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2. Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 3. Have open sore or open lesions in the treatment area 4. Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 5. Have participated in any interventional clinical trial in the previous 30 days. 6. Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 7. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. 8. Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

Measure	Time frame
1. change in Skin Sebum 2. change in Acne Count 3. change in Blackheads and Whiteheads 4. Dermat evaluationTimepoint: At D0, D14, D28	—

Secondary

Measure	Time frame
1. Chnage in Pore Size 2. HD Imaging Timepoint: At D0, D28;1. SGA (Subject Global Assessment)Timepoint: At D28	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results